The Hepatitis C Treatment Market to Be Driven By the Use of Natural Language Processing

The Hepatitis C Treatment Market is slated to grow on a stellar note going forward. The current situation is that digitization, which has the capacity of changing the dynamics of any vertical, has made a beeline to the healthcare vertical. The world out there no more depends on references for choosing healthcare services but goes for 360-degree research before arriving at the final decision. This would be the digitized healthcare vertical in the future.

The Hepatitis C Treatment Market is bound to grow robustly in the years to come. With smart technology and 5G being increasingly adopted, the healthcare vertical is witnessing a paradigm shift. These technologies can thus increase the convenience quotient (CQ), as abysmal disruption happens in the patients' lives. This convenience quotient would be the trend running in the healthcare vertical shortly.

Persistence Market Research (PMR) delivers key insights on the global hepatitis C treatment market in its latest report titled "Hepatitis C Treatment Market: Global Industry Analysis and Forecast, 2016-2024". The global hepatitis C treatment market was valued at US$ 23.9 Bn in 2015 and is estimated to be valued at US$ 26.6 Bn by 2016. The market is expected to reach a valuation of US$ 71.13 Bn by the end of 2024, reflecting a CAGR of 13.1% over the forecast period.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/3602

Company Profiles

Gilead Sciences, Inc.
AbbVie Inc.
Kadmon Holdings, Inc.
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc.
Bristol-Myers Squibb Company
Merck & Co., Inc.
Johnson & Johnson
Others.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/3602

Market dynamics

Growth of the global hepatitis C treatment market is primarily driven by factors such as increase in the prevalence of hepatitis C infections in the U.S. and Canada and rising per capita healthcare expenditure across the globe.

Also government initiatives to control infection and various private NGOs creating awareness about treatment is also fueling the market growth. However, high cost associated with hepatitis C treatment drugs and lack of awareness about hepatitis C infection in the regions of Asia Pacific, Middle East and Africa, and Latin America is expected to impede growth of the global hepatitis C treatment market.

Market forecast

By drug class, the market is segmented into HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral which is again sub-divided into various drugs sub segments. The combination segment is expected to contribute a maximum share to the global hepatitis C treatment market and register the fastest CAGR of 13.9% during the forecast period.

By distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Among these, the hospital pharmacies segment is anticipated to be dominant throughout the forecast period and is projected to account for about 43.7% share of the total global hepatitis C treatment market revenue by 2024.

The hospital pharmacies segment is anticipated to emerge as the most attractive segment in the global hepatitis C treatment market owing to growing instances of hospitalization and improved accessibility and services. The online pharmacies segment is expected to register the fastest CAGR during the forecast period and is estimated to create absolute $ opportunity of US$ 713.8 Mn in 2017 over 2016. The online pharmacies segment is expected to witness significant growth during the forecast period and this can be attributed to high availability of hepatitis C treatment drugs and discounts provided by online pharmacies.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/3602

This report covers global and regional trends along with an analysis of the market potential. North America is estimated to account for 45% share in the global hepatitis C treatment market by 2016, whereas Asia Pacific is projected to grow at a healthy CAGR of 14.8% due to increasing awareness about hepatitis C infections.

Europe region is expected to account for 19.6% share in the global hepatitis C treatment market by 2016 end. Latin America was valued at US$ 2,915.8 Mn in 2015 and is estimated to reach US$ 3,311.1 Mn by 2016, with a Y-o-Y growth of 13.6% over 2015-2016. The Middle East and Africa region was valued at US$ 1,792.5 Mn in 2015 and is estimated to reach US$ 1,988.1 Mn by 2016.

Access Related Reports-

Rare Endocrine Disease Treatment Market: https://www.persistencemarketresearch.com/market-research/rare-endocrine-disease-treatment-market.asp

Home Infusion Therapy Market: https://www.persistencemarketresearch.com/market-research/home-infusion-therapy-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.